Eesti - eesti - Ravimiamet

norameda uab - deksametasoon - tablett - 4mg 30tk; 4mg 100tk; 4mg 20tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - immunosupressandid - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Euroopa Liit - eesti - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - transplantaadi tagasilükkamine - immunosupressandid - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Eesti - eesti - Ravimiamet

lex ano uab - deksametasoon - tablett - 4mg 20tk

Eesti - eesti - Ravimiamet

fresenius kabi polska sp. z o.o. - deksametasoon - süstelahus - 4mg 1ml 2ml 50tk; 4mg 1ml 1ml 10tk

Eesti - eesti - Ravimiamet

ideal trade links uab - asatiopriin - õhukese polümeerikattega tablett - 50mg 100tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - immunosupressandid - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.

Eesti - eesti - Ravimiamet

ideal trade links uab - deksametasoon - tablett - 4mg 28tk; 4mg 56tk; 4mg 100tk

Eesti - eesti - Ravimiamet

ideal trade links uab - deksametasoon - tablett - 20mg 10tk; 20mg 50tk; 20mg 30tk; 20mg 20tk

Eesti - eesti - Ravimiamet

medochemie limited - deksametasoon - süste-/infusioonilahus - 4mg 1ml 2ml 5tk; 4mg 1ml 2ml 100tk